7,507.47

-42.47

-0.56%

52,213.25

-176.50

-0.34%

24,985.64

-267.50

-1.06%

2,816.00

-24.81

-0.87%

4.9920

+0.1280

+2.63%

20.05

+0.13

+0.65%

4,038.40

-76.10

-1.85%

73,264.46

-1,514.54

-2.03%

Crude Oil Dec 26

86.17

-0.68

-0.78%

US Private Equity

10,850.15

0.00

0.00%

NasdaqCM - Nasdaq Real Time Price USD

BriaCell Therapeutics Corp. (BCTX)

3.7100 +0.0150 (+0.41%)

As of 1:31:48 PM EST. Market Open.

Loading Chart for BCTX

Chart Range Bar

Interval:

In partnership with ChartIQ

BriaCell and BriaPro Present Positive Preclinical Immunotherapy Data Across Four Posters at SITC 2026

BriaCell and BriaPro Present Positive Preclinical Immunotherapy Data Across Four Posters at SITC 2026

BriaCell Awarded 2026 “Immunotherapy Solution of the Year” By BioTech Breakthrough

BriaCell Awarded 2026 “Immunotherapy Solution of the Year” By BioTech Breakthrough

BriaCell and BriaPro to Present Preclinical Anti-Cancer Activity and Immunotherapy Findings at SITC 2026

BriaCell and BriaPro to Present Preclinical Anti-Cancer Activity and Immunotherapy Findings at SITC 2026

BriaCell Announces ESMO 2026 Poster Highlighting Circulating Immune Biomarker Associated with Clinical Outcomes in Metastatic Breast Cancer

BriaCell Announces ESMO 2026 Poster Highlighting Circulating Immune Biomarker Associated with Clinical Outcomes in Metastatic Breast Cancer

BriaCell and BriaPro to Present Four Posters at SITC 2026 Annual Meeting

BriaCell and BriaPro to Present Four Posters at SITC 2026 Annual Meeting

Data Safety Monitoring Board (DSMB) Recommends Continuing BriaCell’s Phase 3 Metastatic Breast Cancer Study

Data Safety Monitoring Board (DSMB) Recommends Continuing BriaCell’s Phase 3 Metastatic Breast Cancer Study

BriaCell’s Pivotal Phase 3 Metastatic Breast Cancer Study Expands to Leading Cancer Center

BriaCell’s Pivotal Phase 3 Metastatic Breast Cancer Study Expands to Leading Cancer Center

BriaCell Opens First Canadian Site – Sunnybrook – for Pivotal Phase 3 Trial in Metastatic Breast Cancer

BriaCell Opens First Canadian Site – Sunnybrook – for Pivotal Phase 3 Trial in Metastatic Breast Cancer

BriaCell Arranges Scalable Manufacturing with FUJIFILM Biotechnologies for Bria-IMT™

BriaCell Arranges Scalable Manufacturing with FUJIFILM Biotechnologies for Bria-IMT™

BriaCell Engages Consulting and Branding Firms to Support Commercial and Market Access Evaluation of Bria-IMT™

BriaCell Engages Consulting and Branding Firms to Support Commercial and Market Access Evaluation of Bria-IMT™

BriaCell Presents Positive Clinical Data at ASCO 2026

BriaCell Presents Positive Clinical Data at ASCO 2026

Mobilize your Website

View Site in Mobile | Classic

Share by: